Following a surge of 52.47% during regular trading session on Tuesday, Polyrizon Ltd (NASDAQ: PLRZ) witnessed a dip of 12.02% ...

Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap ...

With this agreement, Polyrizon secures a reliable and compliant manufacturing source for the PL-14 clinical trial. The trial aims to evaluate the safety and efficacy of PL-14 as an allergy blocker ...

Polyrizon Ltd., a biotech company in Israel, has announced a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S, a reputable EU-based Good Manufacturing Practice (GMP) manufacturer ...

Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap ...

Polyrizon Ltd., a biotech company based in Raanana, Israel, announced a successful preliminary safety study for its PL-14 Allergy Blocker, an innovative intranasal hydrogel designed to provide a ...

Raanana, Israel, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in the development of innovative medical device ...

Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap ...

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial Dec. 02, 2024 8:02 AM ET Polyrizon Ltd. (PLRZ) ...

Polyrizon Ltd. set terms for its initial public offering on Friday, with plans to offer 3.1 million units priced at $5.20 to $7.20 a pop. Each unit will consist of one ordinary share and three ...